It has been hailed by Donald Trump as a breakthrough treatment, and it is hoped that coronavirus-containing blood plasma covid-19 may help British patients during the second wave.
But a study, published in it British Medical Journal (BMJ) on Friday, suggests that “convulsive plasma” has only a limited effect and fails to reduce mortality or prevent the progression of severe disease.
Plasma is the clear, yellow liquid part of the blood that carries red and white blood cells and platelets around the body. After infection, plasma is often filled with antibodies produced by the immune system. Thus, it is sometimes taken from people who have recovered from an illness and transmitted it to patients who are fighting it. This abundant plasma therapy was used in 1918 to treat flu epidemics as well as SARS or Ebola patients during the recent global health emergency.
Numerous cases are being investigated around the world to determine if plasma-assisted reduction of deaths and serious complications from coyote-19 could lead to the largest randomized controlled trial in the UK.
Despite the findings of the latest published study, controlling plasma against Cold 19 may still be effective.
The study included 464 adults of moderate code 19 who were admitted to hospitals in India between April and July. With standard care, approximately half of the individuals received two plasma transfusions over a 24-hour period, while the control group received only standard care.
One month later, 19% of those who received plasma had developed a serious illness or died of any cause, compared to 18% in the control group. However, in plasma therapy, the symptoms, such as shortness of breath and fatigue, were reduced after seven days.
NHS Blood and Transplant Spokesperson Plasma accumulation From the people who recovered from Covid-19, it was emphasized that the UK-based studies were only infusion plasma with high levels of coronavirus antibodies. He said that the use of antibody plasma in Indian studies is six to ten times less.
Indian researchers agree that further studies using high levels of antibodies may be more effective. A trial at Houston Methodist Hospital in Texas, in a preliminary analysis of 136 Cowide 19 patients, suggested a significant reduction in mortality in patients who were initially exposed to high levels of plasma with these antibodies.
The follow-up data of all 351 patients in the Texas study has been published as a publication. Pre-print And supports this conclusion, although plasma transfusions later in the disease did not have a significant effect on disease rates. “In terms of morbidity and mortality, our analysis identified an excellent window for covid-19 patients to be admitted to the hospital 44 hours after the death of high-titer convulsant plasma,” he wrote. Written
Professor Paul Morgan, director of the Systems Immunity Research Institute at Cardiff University and a member of the British Society for Immunology’s Task Force on Immunology and Coyote-19, said there were other reasons for optimism. For one thing, he said, the study states that plasma therapy is associated with a reduction in viral load, “therefore, an antiviral effect of the therapy is known, even if it does not appear in the final results.” Is”.
The study also indicated that influencing patients with large amounts of donated plasma could lead to a small but significant increase in mortality. “It would be worth considering instead of simply giving a protective plasma, removing antibodies from the plasma and using them,” Morgan said. Such purified antibodies are already used to treat patients with antibody deficiency.
STAY TUNED WITH US FOR MORE INTERESTING CONTENT ONLY ON DESINEW.XYZ